What drove the significant increase in net earnings this quarter?

The significant increase in net earnings was primarily driven by a substantial increase in sales across both the Innovative Medicine and MedTech segments, coupled with a substantial reversal of a portion of the previously accrued talc reserve. This reversal significantly reduced 'Other (income) expense, net' compared to the prior year.

How did the recent acquisitions of Intra-Cellular Therapies and Shockwave Medical impact the results?

The acquisition of Intra-Cellular Therapies contributed to the growth in the Neuroscience sub-segment within Innovative Medicine, adding CAPLYTA and a promising pipeline. The Shockwave Medical acquisition significantly boosted the Cardiovascular franchise within the MedTech segment, driving operational sales growth.

What is the impact of biosimilar competition on STELARA sales?

Biosimilar competition, particularly with the expected launches in Europe and the United States in 2025, continues to significantly impact STELARA sales. This decline had an approximate 11.7% negative impact on worldwide Innovative Medicine operational sales in Q2 2025.

How is Johnson & Johnson managing its legal liabilities, particularly related to talc and opioids?

Johnson & Johnson continues to manage its significant legal liabilities. The talc reserve was significantly reduced this quarter due to the dismissal of a bankruptcy case, although a substantial reserve remains. The company has settled the majority of state and subdivision opioid claims and continues to defend against remaining government and private litigants.

JNJ 10-Q Quarterly Report Q2 FY2025 — Revenue, Net Income, EPS

Summary

Johnson & Johnson (JNJ) reported a strong second quarter for fiscal year 2025, demonstrating robust sales growth and improved profitability. Worldwide sales increased by 5.8% to $23.7 billion, driven by solid performance across both the Innovative Medicine and MedTech segments. The Innovative Medicine segment saw a notable 4.9% increase in sales, propelled by strong oncology product performance, particularly from CARVYKTI and DARZALEX, alongside the recent acquisition of Intra-Cellular Therapies contributing to the neuroscience portfolio. The MedTech segment also delivered a healthy 7.3% sales increase, benefiting from the integration of Shockwave Medical and continued strength in cardiovascular and surgical solutions. Net earnings significantly rose to $5.5 billion, or $2.29 per diluted share, compared to $4.7 billion, or $1.93 per diluted share, in the prior year's quarter. This increase was significantly aided by the reversal of a substantial portion of the previously accrued talc reserve, which contributed positively to the 'Other (income) expense, net' line item. The company maintained its commitment to shareholders through dividend payments and share repurchases, underscoring a positive financial outlook.

Financial Highlights

51 data points

Beta

Revenue

$23.74B

0.7% Gross Margin

Net Income

$5.54B

0.2% Net Margin

EPS (Diluted)

$2.29

Total Assets

$193.39B

Cash & Equivalents

$18.58B

Free Cash Flow

$2.83B

Financial Statements

Beta

Revenue	$23.74B
Cost of Revenue	$7.63B
Gross Profit	$16.11B
SG&A Expenses	$5.89B
Net Income	$5.54B
EPS (Basic)	$2.30
EPS (Diluted)	$2.29
Shares Outstanding (Basic)	2.41B
Shares Outstanding (Diluted)	2.42B

Key Highlights

1Worldwide sales increased 5.8% to $23.7 billion in Q2 2025.
2Innovative Medicine segment sales grew 4.9% to $15.2 billion, driven by strong oncology growth and the Intra-Cellular acquisition.
3MedTech segment sales increased 7.3% to $8.5 billion, boosted by the Shockwave acquisition.
4Net earnings surged to $5.5 billion ($2.29 per diluted share) from $4.7 billion ($1.93 per diluted share) in Q2 2024.
5The reversal of a significant portion of the talc reserve positively impacted "Other (income) expense, net."
6R&D expenses decreased as a percentage of sales in both segments, indicating improved efficiency.
7The company maintained a strong liquidity position with $18.6 billion in cash and cash equivalents.

JOHNSON & JOHNSON Quarterly Report for Q2 Ended Jun 29, 2025

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions